DAPK2 is emerging as a tumour suppressor in several types of cancer cells, especially in acute promyelocytic leukaemia, which responds to treatment with all-trans retinoic acid (ATRA).12 This is interesting as ATRA leads to increased DAPK2 expression. The gene discussed is DAPK2; the disease is neoplasm.